Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 190,604 shares at $41.52 ($7.8M) on 2021-09-27, disclosed to the SEC on 2021-09-29.
Open-market sale of $7.8M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.51 | 27,373 | $1.1M | 14.1% |
| 2 | $40.51 | 17,854 | $723K | 9.2% |
| 3 | $40.51 | 17,854 | $723K | 9.2% |
| 4 | $40.51 | 27,373 | $1.1M | 14.1% |
| 5 | $41.52 | 13,233 | $549K | 7.0% |
| 6 | $41.52 | 13,233 |
| $549K |
| 7.0% |
| 7 | $41.52 | 20,292 | $843K | 10.7% |
| 8 | $41.52 | 20,292 | $843K | 10.7% |
| 9 | $42.29 | 10,018 | $424K | 5.4% |
| 10 | $42.29 | 6,532 | $276K | 3.5% |
| 11 | $42.29 | 10,018 | $424K | 5.4% |
| 12 | $42.29 | 6,532 | $276K | 3.5% |
| Total | $41.17 avg | 190,604 | $7.8M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |